Lupus Science & Medicine
Open Access Publication
Rights and Permissions
Neupane B, Shukla P, Slim M, et alBelimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeksLupus Science & Medicine 2023;10:e000907. doi: 10.1136/lupus-2023-000907© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Neupane, Binod; Shukla, Pragya; Slim, Mahmoud; Martin, Amber; Petri, Michelle; Bertsias, George K.; Kim, Alfred H J; Fanouriakis, Antonis; Levy, Roger A.; Chauhan, Deven; and Ballew, Nick, "Belimumab versus anifrolumab in adults with systemic lupus erythematosus: An indirect comparison of clinical response at 52 weeks." Lupus Science & Medicine. 10, 1. e000907 (2023).
ICTS (Institute of Clinical and Translational Sciences)